Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey
dc.contributor.author | Hacioglu, Muhammet Bekir | |
dc.contributor.author | Kostek, Osman | |
dc.contributor.author | Karabulut, Senem | |
dc.contributor.author | Tastekin, Didem | |
dc.contributor.author | Goksu, Sema Sezgin | |
dc.contributor.author | Alandag, Celal | |
dc.contributor.author | Akagunduz, Baran | |
dc.date.accessioned | 2024-04-24T17:33:46Z | |
dc.date.available | 2024-04-24T17:33:46Z | |
dc.date.issued | 2020 | |
dc.department | Dicle Üniversitesi | en_US |
dc.description.abstract | Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting. Methods: In this retrospective and multicenter study, advanced HCC patients not eligible for local therapies, who received a secondor third-line regorafenib therapy after progression on the first-line sorafenib or sequential therapy with chemotherapy (CT) followed by sorafenib, were included. Results: In the first-line setting, 28 (28.9%) patients received CT and 69 (71.1%) patients received sorafenib. There were 24 (24.7%) patients who were intolerant to sorafenib. Disease control rate (DCR) was 53.6% for all patients treated with regorafenib, 62.3% in patients who received regorafenib in the second-line, and 32.1% for those receiving regorafenib in the third-line (p=0.007). Median progression-free survival (PFS) and overall survival (OS) were 5.6 (range; 4.3-6.9) and 8.8 (range, 6.3-11.3) months for all patients treated with regorafenib vs. 7.1 months and 10.3 months for patients who received regorafenib in the second-line vs. 5.1 and 8.7 months for patients who received regorafenib in the third-line, respectively; however, there was no statistically significant difference (p(PFS)=0.22 and p(OS)=0.85). Conclusion: Although receiving CT as a first-line therapy in advanced HCC patients did not affect the survival rates of subsequent regorafenib therapy, it might diminish the DCR of regorafenib. | en_US |
dc.identifier.endpage | 1903 | en_US |
dc.identifier.issn | 1107-0625 | |
dc.identifier.issn | 2241-6293 | |
dc.identifier.issue | 4 | en_US |
dc.identifier.pmid | 33099930 | |
dc.identifier.scopus | 2-s2.0-85090483650 | |
dc.identifier.scopusquality | Q3 | |
dc.identifier.startpage | 1897 | en_US |
dc.identifier.uri | https://hdl.handle.net/11468/20836 | |
dc.identifier.volume | 25 | en_US |
dc.identifier.wos | WOS:000573102800001 | |
dc.identifier.wosquality | Q4 | |
dc.indekslendigikaynak | Web of Science | |
dc.indekslendigikaynak | Scopus | |
dc.indekslendigikaynak | PubMed | |
dc.language.iso | en | en_US |
dc.publisher | Imprimatur Publications | en_US |
dc.relation.ispartof | Journal of Buon | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Hepatocellular Carcinoma | en_US |
dc.subject | Regorafenib | en_US |
dc.subject | Disease Control Rate | en_US |
dc.subject | Overall Survival | en_US |
dc.subject | Chemotherapy | en_US |
dc.subject | Anti-Vegf Therapy | en_US |
dc.title | Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey | en_US |
dc.title | Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey | |
dc.type | Article | en_US |